5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulmatrix Inc. (NASDAQ:PULM) reported that 5am Ventures Llc. has picked up 251,188 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by 5am Ventures Llc. to a total of 251,188 representing less than 1.41% stake in the company.

For those not familiar with the company, Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

A glance at Pulmatrix Inc. (NASDAQ:PULM)’s key stats reveals a current market capitalization of 53.11 Million based on 17.83 Million shares outstanding and a price at last close of $3.23 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-06-15, Mcguire picked up 1,392 at a purchase price of $6.88. This brings their total holding to 52,722 as of the date of the filing.

On the sell side, the most recent transaction saw Oculus unload 922,500 shares at a sale price of $2.75. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulmatrix Inc. (NASDAQ:PULM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Author: Richard Schwarz

Richard Schwarz is a veteran analyst in the small cap space, with a particular focus on the development stage biotech sector. He is a native of Canada, and attended NYU before working for a host of big name pharma outfits.

Share This Post On

Submit a Comment

Your email address will not be published. Required fields are marked *